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Abstract Clostridial collagenases are foe and friend: on the
one hand, these enzymes enable host infiltration and
colonization by pathogenic clostridia, and on the other
hand, they are valuable biotechnological tools due to their
capacity to degrade various types of collagen and gelatine.
However, the demand for high-grade preparations exceeds
supply due to their pathogenic origin and the intricate
purification of homogeneous isoforms. We present the
establishment of an Escherichia coli expression system for
a variety of constructs of collagenase G (ColG) and H
(ColH) from Clostridium histolyticum and collagenase T
(ColT) from Clostridium tetani, mimicking the isoforms in
vivo. Based on a setup of five different expression strains and
two expression vectors, 12 different constructs were
expressed,andaflexiblepurificationplatformwasestablished,
consisting of various orthogonal chromatography steps adapt-
able to the individual needs of the respective variant. This fast,
cost-effective, and easy-to-establish platform enabled us to
obtain at least 10 mg of highly pure mono-isoformic protein
per liter of culture, ideally suited for numerous sophisticated
downstream applications. This production and purification
platform paves the way for systematic screenings of recom-
binant collagenases to enlighten the biochemical function and
to identify key residues and motifs in collagenolysis.
Keywords Clostridialcollagenases.Expression.
Purification.Platform
Introduction
Clostridia comprise a diverse family of anaerobic, sporu-
lating bacteria, including notorious pathogenic species
such as Clostridium botulinum, Clostridium perfringens,
and Clostridium difficile. Two further prominent represen-
tatives are Clostridium histolyticum, a pathogen-causing gas
gangrene, and Clostridium tetani giving rise to tetanus
(Bruggemann et al. 2003;B u r k ea n dO p e s k i n1999; Sasaki
et al. 2000). While the histotoxicity of Clostridia is primarily
caused by specific toxins (Hatheway 1990), host infiltration
and colonization are triggered by the production of various
proteases such as collagen degrading zinc-metalloproteases,
namely collagenases (Bruggemann and Gottschalk 2004;
Hatheway 1990;M a l l y ae ta l .1992) and polysaccharide—
and lipid—degrading enzymes (Matsushita and Okabe 2001).
Therefore, clostridial collagenases have been proposed as
important drug-target candidates.
Additionally, with collagens being the most abundant
proteins in all higher organisms, there exists a diverse
spectrum of therapeutic and biotechnological applications
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cally well-characterized ColG and H from C. histolyticum,
including their use for islet cell isolation, wound healing,
treatment of retained placenta, or their use as additives to
laundry detergents, to name a few (Chu 1987; Haffner et al.
1998; Hesse et al. 1995; Sank et al. 1989; Watanabe 2004).
All currently classified clostridial collagenases are
members of the MEROPS peptidase subfamily M9B
(Rawlings et al. 2006). They are mosaic proteins consisting
of a signal peptide, a catalytic domain, up to two polycystic
kidney disease domain(s) (PKD) of unknown function and
up to three collagen binding domain(s) (CBD; see Fig. 1).
Their domain organization varies significantly. For exam-
ple, ColG and ColA from C. perfringens possess a
duplicated CBD and a single PKD. In ColH, the latter is
duplicated, whereas it is completely absent in ColT from C.
tetani (Bruggemann and Gottschalk 2004; Watanabe 2004).
Contrasting the zinc coordination in metzincins (e.g.,
mammalian collagenases), bacterial collagenases as gluzin-
cins employ a glutamate as third catalytic zinc binding
ligand next to the two histidines in the canonical HEXXH
motif of the zincin superfamily (Jung et al. 1999). The
structuralknowledge about the clostridialcollagenasesispoor
and currently confined to the crystal structure of the CBD
(Wilson et al. 2003) that has been shown to bind to collagen
in a cooperative and calcium dependent manner (Matsushita
et al. 1998; Toyoshima et al. 2001; Wilson et al. 2003).
The high biotechnological and medical interest in
clostridial collagenases that is mirrored by an increasing
demand for high grade mono-isoformic preparations, in
particular of ColG and ColH, faces a shortage of supply due
to (1) the pathogenic origin of ColH and ColG and (2) the
intricacy associated with the purification of homogeneous
isoforms. The development of simple and efficient high-
level expression and purification strategies would also
facilitate basic and applied research of bacterial collage-
nases. Reported recombinant expression trials focused on
Bacillus subtilis, C. perfringens, and Escherichia coli as
expression systems. (1) Bacillus subtilis enabled the
secretory expression of ColG and ColH, but the expression
system suffered from plasmid instability and low protein
yields (Jung et al. 1996). The latter was attributed to the
remarkably high A + Tcontent of clostridial genes and their
biased codon usage (Sharp et al. 2005; Tanaka et al. 2008).
(2) Bypassing these drawbacks associated with heterolo-
gous expression, Tanaka et al. developed a protease-
deficient C. perfringens strain 13 expression system and
were able to purify mg amounts of homogeneous ColH
(Tamai et al. 2008; Tanaka et al. 2008). (3) Already in
1995, Hesse et al. utilized non-pathogenic E. coli strains for
the recombinant expression of clostridial collagenases,
exploiting the short generation times, easy handling and
the well established fermentation know-how of this host,
resulting in expression yields several fold higher than in the
natural host (Hesse et al. 1995).
Although the latter expression system was considered as
inefficient in translating clostridial genes (Tanaka et al.
2008), we report the production and purification of mg
amounts of high-grade mono-isoformic clostridial collage-
nases preparations on a small laboratory scale. The
established protein expression and purification platform
provides cost-efficient access to these biotechnologically
important enzymes and paves the way for systematic
enzyme engineering approaches.
In our study, we selected three bacterial collagenases:
ColG, H, and T that are characterized by complementary
domain architectures (Fig. 1). A variety of constructs
(Table 1), reflecting this mosaicity, was designed and
combined with two types of expression plasmid (Fig. 2):
in the first, the recombinant proteins were fused to an
N-terminal His6-tag; the second plasmid allowed a tandem-
tag strategy, combining an N-terminal cleavable maltose
binding protein (MBP)-tag and a C-terminal His6-tag. These
tagging variants facilitated highly efficient purification
strategies that allowed us to achieve both high yield (at least
10 mg/l of culture range) and homogeneous (>95% based on
Coomassie stained SDS-PAGE) protein preparations.
Materials and methods
Materials
Plasmids encoding for ColG (GenBank: D87215.1) and
ColH (GenBank: D29981.1) were obtained from Roche
Diagnostics, Penzberg (Germany). The genomic DNA of
Fig. 1 Schematic representation
of the domain architecture of
three different mature clostridial
collagenases. PKD polycystic
kidney disease domain; CBD
collagen binding domain
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Appl Microbiol Biotechnol (2009) 83:1055–1065 1057Clostridium tetani strain E88 (GenBank: NC_004557) was
obtained from Göttingen Genomics Laboratory, Göttingen
(Germany).
Restriction enzymes and T4 Ligase were obtained from
Fermentas, St. Leon-Rot (Germany). Pfu Ultra II™ Fusion
HS DNA Polymerase was obtained from Stratagene, La
Jolla (USA). Custom-made primers were obtained from
Eurofins MWG Operon, Ebersberg (Germany), and se-
quence analyses were performed at Eurofins MWG Operon,
Martinsried (Germany).
E. coli strain XL1 Blue (Stratagene, La Jolla, USA) was
used for subcloning. Strains BL21, BL21 DE3, Tuner DE3,
Origami DE3, and Rosetta DE3 (Novagen, Madison, USA)
were used as host strains for protein expression. For
expression, LB-Lennox (Roth, Karlsruhe, Germany) was
used. All reagents were of the highest standard available from
Sigma–Aldrich Co., München (Germany) or AppliChem,
Darmstadt (Germany).
Cloning
The encoding DNA fragments were amplified by polymer-
ase chain reaction(PCR; Eppendorf mastercycler ep gradient
thermal cycler)using genomicDNA (ColT) orplasmidDNA
(ColG and H) as template and appropriate primer containing
the restriction sites for subsequent cloning (Tables 2 and 3).
PCR products were purified with MinElute PCR Purifica-
tion Kit (Qiagen, Hilden, Germany) and digested with the
appropriate restriction enzymes, ligated under standard
conditions, and introduced into XL1 Blue cells via electro-
poration by standard protocols. All inserts were cloned in
a modified pET15b expression vector encoding for an
N-terminal His6-tag followed by a TEV (Tobacco Etch
Virus protease) cleavage site for specific tag removal.
Constructs intended for tandem affinity purification via a
TEV-cleavable N-terminal MBP-tag and a non-cleavable
C-terminal His6-tag were cloned in the expression vector
pMBP-Parallel2 (Sheffield et al. 1999). All constructs were
confirmed by DNA sequencing prior to protein expression.
Expression of ColG, H, and T
Test expression and solubility testing Plasmids were intro-
duced into expression hosts via electroporation. Three
milliliter of LB media containing the appropriate antibiotics
were inoculated with a single bacterial colony from a fresh
LB-agar plate and incubated at 37 °C with vigorous shaking
(230 rpm) overnight. 50 µl of the overnight cultures were
diluted 1:1,000 in fresh LB medium, containing the
appropriate antibiotics, and incubated at 37 °C with shaking
in 250-ml baffled flasks until the bacterial cultures reached
the planned optical density. After induction, cultures were
transferred to the respective temperature and allowed to
grow for at least additional 4 h. Cells were harvested by
centrifugation for 20 min at 5,000×g and 4 °C. Parameters
considered for optimization in terms of maximizing soluble
expression were: (1) different E. coli strains (given above),
(2) final isopropyl-ß-D-thiogalactoside (IPTG) concentra-
tions (0.1, 1.0 mM), (3) cell densities at point of induction
(OD600 0.8, 1.2), (4) expression temperatures (25 and 37 °C),
and (4) duration of expression (4 h, ON). In sum, 64
different expression conditions were tested for every con-
struct. Parameters found optimal were used for large-scale
expressions.
Fig. 2 Schematic representation of the expression vectors. a pET15b and b pMBP-Parallel2
1058 Appl Microbiol Biotechnol (2009) 83:1055–1065Large-scale expression and cell harvest Large-scale ex-
pression was carried out in the respective E. coli strains under
the identified conditions (Table 1). Cells were harvested by
centrifugation for 20 min at 4,000×g a n d4° C .P e l l e t sw e r e
resuspended in a buffer containing 50 mM NaH2PO4,
10 mM Tris, 150 mM NaCl, 10 mM imidazole, pH 8.0,
and subsequently sonicated intermittently on ice (5×30 s,
45 W). Cell debris was removed by centrifugation (×2) for
30 min at 15,000×g and 4 °C.
Purification and activity assay of ColG, ColH, and ColT
All purification steps were performed at 4 °C or with
precooled buffers.
Immobilized metal affinity chromatography Purification
was carried out in batch mode with pre-equilibrated
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole,
pH 8.0) Ni-NTA Superflow resin (Qiagen, Hilden, Ger-
many). Cleared lysate was loaded onto the resin and
washed at least twice with buffer containing various
imidazole concentrations (buffer given above with 20–
40 mM imidazole). Target protein was eluted in a single
step with a high imidazole buffer (250 mM imidazole).
Amylose affinity chromatography Purification via the MBP
tag was carried out in batch mode. Amylose resin (New
England BioLabs, Frankfurt, Germany) was pre-
equilibrated with MBP-purification buffer (20 mM Tris,
200 mM NaCl, pH 7.5), protein was loaded and washed at
least twice with MBP purification buffer. MBP-tagged
protein was eluted with the buffer given above supple-
mented with 10 mM maltose.
Removal of the N-terminal tag The N-terminal tag was
removed using the Tobacco Etch Virus protease in a molar
ratio of 1:5 or 1:20 (enzyme to target protein) in a buffer
containing 50 mM Tris, 50 mM NaCl, 1 mM EDTA, and
2 mM DTT at pH 7.5 and 4 °C for 12 to 48 h. To check the
completeness of TEV digest, a re-chromatography on a
Ni-NTA column in batch format was performed.
Ion exchange chromatography For ion exchange chroma-
tography (IEC), the ÄKTA FPLC system and a Q-Sepharose
Column (HiPrep™ 16/10 Q FF; GE Healthcare) were used.
The protein sample was rebuffered via dialysis into salt-free
buffer and filtered before loading onto the pre-equilibrated
column (50 mM MES, pH 6.5). Application of the sample
occurred at a flow rate of 0.2 ml/min to alleviate binding. The
target protein was eluted with a high salt and low pH buffer
(50 mM MES, 1.0 M CaCl2, pH 4.0) using a step gradient at
a flow rate of 0.6 ml/min.
Size exclusion chromatography As final polishing step, the
concentrated (by ultrafiltration) and filtrated protein sample
was loaded onto a Superdex 200 10/300 GL (GE Health-
care) column on the ÄKTA FPLC system. The buffer used
for size exclusion chromatography (SEC) contained 25 mM
Tris, 50 mM NaCl, pH 7.5.
Table 2 Sequences of oligonucleotide primers used for the cloning into pET15b vector
Vector Construct Primer Sequence
pET15b ColG hG Forward KpnI site: 5′-ACGT GGTACC ATGTATGATTTTGAGTATTTAAATG-3′
hG1: S1 Reversed BamHI site: 5′-ACGT GGATCC TTACCCATTATCTGTTAAAACCC-3′
hG2: S1S2 Reversed BamHI site: 5′-ACGT GGATCC TTAGTTCTTTATTTCTATAGTAA-3′
hG3: S1S2S3a Reversed BamHI site: 5′-ACGT GGATCC TTATCCTTTTATGTTTAAAGAAT-3′
hG4: S1S2S3a3b Reversed BamHI site: 5′-ACGT GGATCC TTATTTATTTACCCTTAACTCAT-3′
ColH hH Forward KpnI site: 5′-ACGT GGTACC ATGGTACAAAATGAAAGTAAGAG-3′
hH0 “mini” Reversed BamHI site: 5′-AGCA GGATCC CTATAATATACCCATATCTTTATTATAC-3′
hH1: S1 Reversed BamHI site: 5′-ACGT GGATCC TTATAAATATCCGTGGAATACTA-3′
hH2: S1S2a Reversed BamHI site: 5′-ACGT GGATCC TTAATCTCTTATTTCTGCAGTAG-3′
hH3: S1S2a2b Reversed BamHI site: 5′-ACGT GGATCC TTAATCTGTAATCTTAATCTTCA-3′
hH4: S1S2a2bS3 Reversed BamHI site: 5′-CCCC GGATCC TTATTCTATATTAATTCTATATG-3′
ColT hT Forward KpnI site: 5′-GG GGTACC TACAAAACAAAGTATTCTTTTAATG-3′
hT0 “mini” Reversed XhoI site 5′-CCG CTCGAG TCATGCAAAAAATTCTGCAGAGCCTTC-3′
hT1: S1 Reversed BamHI site: 5′-CCG GGATCC TCATAATAATCCATGGAAAACTATATCATA -3′
hT3: S1S3a3b Reversed XhoI site 5′-CCG CTCGAG TTAATTTATTATTACTGAATAATTACC-3′
Lowercase letter indicates the cleavable N-terminal tag (h: His6), capital letter the respective collagenase (G, H or T), and the digit gives/denotes
the number of domains present in the construct. S1 catalytic domain; S2 PKD domain; S3 CBD
Appl Microbiol Biotechnol (2009) 83:1055–1065 1059Activity assay The biological activity of the clostridial
collagenases was tested after Ni-NTA purification using
N-(3-[2-Furyl]-Acryloyl)-Leu-Gly-Pro-Ala (FALGPA) as a
synthetic substrate (Van Wart and Steinbrink 1981).
SDS-PAGE and protein quantitation
Routinely, expression and purification results were moni-
tored by SDS-PAGE. Samples were resuspended in or
mixed with 2×SDS buffer and separated by SDS-PAGE.
Depending on the molecular weight of the target protein,
10%, 12%, or 15% (w/v) polyacrylamide gels were used. A
prestained protein ladder was used as size marker (Fermen-
tas), and gels were stained with Coomassie Brilliant Blue
R-250. Protein concentrations were determined by the
Bradford dye binding assay with bovine serum albumin as
standard (Bradford 1976) and/or UV280 measurements.
Results
Construct design and cloning
To gain insights into the structure–function relationship of
the clostridial collagenases G, H, and T, the proteins were
dissected by constructing different recombinant derivatives
of the full length enzymes. To delineate the appropriate
boundaries of the different domains, we combined the
following data: (1) information on the mature N-terminus as
Table 3 Sequences of oligonucleotide primers used for cloning into the pMBP-Parallel2 vector
Lowercase letter indicates the cleavable N-terminal tag (m: MBP), capital letter the respective collagenase (G, H or T), and the digit gives/denotes
the number of domains present in the construct. S1 catalytic domain; S2 PKD domain; S3 CBD
1060 Appl Microbiol Biotechnol (2009) 83:1055–1065described in the literature (Matsushita and Okabe 2001), (2)
information on naturally occurring isoforms, as described
for ColG and ColH from C. histolyticum (Bond and Van
Wart 1984a, b; Matsushita et al. 1999), and ColA from C.
perfringens (Matsushita et al. 1994), and (3) bioinformat-
ical analyses that included multiple sequence alignments
and secondary structure predictions (Tables 2, 3). Thereby,
the initial construct design mimics the domain organization
of collagenase isoforms in vivo. A posteriori, two addition-
al constructs were cloned in response to the presence of a
truncated fragment approximately 25 kDa smaller than the
catalytic domain construct in preparations of ColT: (1) a
truncated variant of the catalytic domain of ColT (Tyr
53–
Ala
506; 55 kDa), ending shortly after the third zinc binding
glutamate and (2) based on the domain boarders predicted
by the CHOP server (Liu and Rost 2004), a shortened
variant of the catalytic domain of ColH (Val
41–Leu
556;
60 kDa).
All constructs, four of ColG, five of H, and three of
ColT (displayed in Table 1), were successfully cloned in a
modified pET15b E. coli expression vector, encoding for an
N-terminal His6-tag followed by a TEV recognition motif
(Fig. 2a). Due to observed protein degradation during
protein purification (data not shown) seven constructs, three
of ColG, and ColH each and one of ColT were subcloned
into the pMBP-Parallel2 vector (Sheffield et al. 2009),
shown in Fig. 2b, encoding an N-terminal TEV-cleavable
MBP-tag and a non-cleavable C-terminal His6-tag, allowing
a tandem purification approach that results in clearly
delimited protein samples.
Optimization of ColG, H, and T protein expression
in E. coli
To maximize soluble protein expression, 64 different
expression conditions, based on five different parameters
(host strain, point of induction, final IPTG concentration,
period, and temperature of expression) were screened for
every construct. Detailed results of the optimized expres-
sion parameters are shown in Table 1. A representative
expression gel of all constructs cloned in pET-15b is shown
in Fig. 3.
To sum up, (1) all pET15b constructs of ColG and ColH
were expressed in BL21 DE3, whereas ColT constructs
showed highest soluble expression levels in Tuner DE3
cells. (2) For maximum soluble expression of the longer
collagenase constructs, time of induction was switched
from OD600 0.8 to 1.2 and expression temperature was
lowered to 25 °C to minimize the accumulation of protein
in inclusion bodies. (3) Cells were induced with 0.1 mM
IPTG in case of pET15b constructs for two simple reasons:
lower IPTG concentrations significantly enhanced the
output of soluble ColT protein, and it was economically
favored for ColG and ColH constructs, because no
difference in soluble expression yield could be observed
upon increasing IPTG concentrations. (4) All pMBP-
Parallel2 constructs were expressed in BL21 at 25 °C for
a prolonged period and at a higher final concentration of
IPTG. (5) In general, ColG showed highest expression
levels, followed by ColT and ColH.
Protein purification
To achieve pure and homogeneous protein samples, it was
necessary to combine diverse purification methods (Fig. 4).
We, therefore, established a flexible purification platform
adaptable to the individual needs of the investigated
constructs. We utilized not only the advantages of well-
characterized fusion tags (His6- and MBP-tag) but also
capitalized on intrinsic properties of the proteins, e.g.,
Fig. 4 Schematic representation of the modular purification platform.
(1) A simple two-step approach consisting of IMAC and SEC was
employed for shorter constructs (hG1, hH0, hH1, hT0). (2) Constructs
of intermediate length were purified in three steps using IMAC, IEC,
and SEC (hG2, hG3, hH2, hH3, hT1). (3) Long and full-length
constructs were cloned in the pMBP-Parallel2 vector and the initial
IMAC step was followed by amylose affinity chromatography (AAC),
prior to IEC and the final SEC step (mG3, mG4, mH3, mH4, mT3).
For the nomenclature, compare also Table 1. IMAC, immobilized
metal affinity chromatography; AAC, amylose affinity chromatogra-
phy; IEC, ion exchange chromatography; SEC, size exclusion
chromatography; pMBP, pMBP-Parallel2
Fig. 3 Expression of ColG, H, and T constructs cloned in pET15b.
For the nomenclature, compare Table 1. M prestained protein ladder.
Lane 1 BL21 DE3 cells before induction; lanes 2–5 hG1, hG2, hG3,
and hG4 constructs of ColG 4 h after induction; lanes 6–9 hH1, hH2,
hH3, and hH4 constructs of ColH 4 h after induction; lane 10 Tuner
DE3 cells before induction; lanes 11–13 hT0, hT1, and hT3 constructs
of ColT
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constructs), for successful purification via IEC. As a final
polishing step SEC was routinely used.
For the catalytic domains of ColG and ColH a simple
two-step approach consisting of a NiNTA and a SEC
purification step was already sufficient to obtain pure
protein (Fig. 5a). But in most cases, at least one additional
orthogonal purification step via IEC had to be applied
(Fig. 5b). For the full length constructs, even a tandem
affinity approach combined with IEC and SEC was
necessary to successfully bypass co-purification of C-
terminally degraded variants (Fig. 5c). N-terminal fusion
tags were routinely removed with TEV protease before or
after the ion exchange chromatography step.
To summarize the individual purification steps: (1)
because all constructs featured an N- or C-terminal His6-
tag, immobilized metal affinity chromatography (IMAC)
was by default used as initial purification step (Fig. 6a).
Most E. coli proteins can be easily removed by this method,
and as a welcome side effect the target protein is
concentrated. (2) Constructs equipped with an additional
affinity tag (MBP) were subsequently purified via amylose
resin allowing for efficient pooling of undegraded protein
with clearly defined termini. (3) To achieve high purity
grade protein samples, it was necessary (with few excep-
tions) to employ another orthogonal purification method.
For this purpose we established a calcium gradient ion
exchange chromatography, which capitalizes on the specific
calcium binding properties of these enzymes. Target
proteins were eluted with approximately 100–125 mM
CaCl2 and analyzed by SDS-PAGE (Fig. 6b). (4) Prior or
after IEC the N-terminal tags were removed and samples
were re-purified by IMAC. In case of ColH and T, it was
necessary to deviate from standard protocols and to
increase incubation time (up to 48 h) and the molar ratio
(up to 5:1) for complete tag removal without observing any
undesired “star” activity (Fig. 6c). (5) Size exclusion
chromatography was performed as a final purification step.
A maximum of 10 mg protein per run was loaded. All
proteins migrated as monomers at the expected molecular
size. A representative SEC run is shown in Fig. 6d. (6)
Based on the established protein production and purifica-
tion platform, we succeeded in obtaining monodisperse and
mono-isoformic protein samples for all variants of ColG, H,
and T.
Enzymatic activity
After the initial IMAC purification step enzymatic activity
of the heterologously expressed enzymes was routinely
checked and confirmed by the FALGPA assay (Van Wart
and Steinbrink 1981). All variants except the two mini-
catalytic domains were active against the synthetic sub-
strate. Consistently, ColH constructs showed the highest
overall activity, followed by ColTand ColG. Representative
turnover numbers after SEC are given for the catalytic
domains of ColH, ColT, and ColG: kcat/KM=59,100, 7,470,
and 130 s
−1 M
−1, respectively (Eckhard et al. 2009). As
expected, enzyme activity of all variants could be reversibly
inhibited by the zinc-specific inhibitor 1,10-phenanthroline
(data not shown).
Discussion
The continuing progress in biotechnological and medical
research is uncovering an ever-growing number of possible
applications for clostridial collagenases, in particular ColG
Fig. 5 Differential purification strategy exemplified by hG1, hG2,
and mG4. For the nomenclature, compare Table 1. M prestained
protein ladder. a Purification of hG1. Lane 1 cleared lysate; lane 2
hG1 after NiNTA purification; lane 3 hG1 without His6-tag after SEC.
b Purification of hG2. Lane 1 cleared lysate; lane 2 hG2 after NiNTA
purification; lane 3 hG1 without His6-tag after IEC; lane 4 hG1
without His6-tag after SEC. c Purification of mG4. Lane 1 cleared
lysate; lane 2 mG4 after NiNTA purification; lane 3 mG4 after
purification via amylose resin. Lane 4 mG4 without MBP-tag after
IEC; lane 5 mG4 without MBP-tag after SEC
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Jordan 2008; Ku et al. 1993; Kuriyama et al. 2001; Segev et
al. 2005; Wang et al. 2004). There are various commercial
preparations available, but these usually contain several
collagenase isoforms and even other proteases (e.g.,
clostripain). Their heterogeneity and the difficulty of
obtaining mono-isoformic preparations have so far hindered
us from exhausting their full biotechnological and medical
potential, such as the development of application-specific
mutants and rational drug design. Therefore, we wanted to
develop a protein production and modular purification
platform that (1) results in large quantities of highly pure
mono-isoformic collagenase samples, (2) is easy to handle,
and (3) straightforward to establish, in short a “kit-like
technology.” By means of the naturally occurring isoforms
accomplished by a molecular dissection of ColG, H, and T,
we could show here the feasibility of our efforts (Table 1).
We employed the working horse of protein expression—
E. coli—and could, thus, fully profit from its properties,
such as its well-understood genetics, inexpensive media,
fast growth rate, and high expression yields (Jana and Deb
2005; Makrides 1996). To optimize the yield of soluble
protein, we tested several expression parameters for all
constructs: (1) E. coli strains with slightly altered expres-
sion characteristics, (2) point of induction, (3) final IPTG
concentration, (4) cultivation temperature, and (5) induction
period. All monitored parameters affected the soluble
protein yield, justifying this comprehensive screening of
Fig. 6 Purification of the catalytic domain of ColT (hT1). For the
nomenclature, compare Table 1. M prestained protein ladder. a Native
Ni-NTA purification of hT1 analyzed by SDS-PAGE: Lane 1 column
flow-through; lanes 2, 3 wash 1, 2; lanes 4, 5 elutions containing hT1.
b Ion exchange chromatography of hT1. This purification step
occurred via ÄKTA FPLC system using a Q-Sepharose column. The
protein was eluted with ~100 mM CaCl2. c Removal of the His6-tag
from hT1. Lanes 1, 2 flow-through containing the target protein
without His6-tag; lanes 3, 4 wash steps; lane 5 elutions containing the
TEV-protease; d Size exclusion chromatography of the catalytic
domain without His6-tag. The first UV peak corresponds to the void
volume of the column (Superdex 200 10/300 GL) and the second to
the catalytic domain of ColT
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protein production and purification.
In a second step, we optimized the purification protocols
based on a flexible arrangement of different chromatographic
techniques (affinity, ion exchange and size exclusion chroma-
tography) to the individual needs of the investigated isoforms
(Fig. 4). For instance, a two step purification approach was
already sufficient for shorter constructs, e.g., the catalytic
domain of ColG (Eckhard et al. 2008), whereas a four-step
approach was necessary for the full-length collagenases to
meet our purity requirements.
Already at an early stage of this project, we observed the
degradation of several constructs by SDS-PAGE analysis
and Western blot (data not shown). The revealed (auto)
degradation pattern of the full-length constructs apparently
correlated roughly with the size of the naturally occurring
isoforms and, therefore, gave additional impetus to the idea
to mimic their mosaic domain architecture with our
constructs. To cope with the degradation problem, we
included a tandem affinity tagging strategy for the longer
constructs (Table 1 and Fig. 4) by fusing a cleavable
maltose binding protein-tag to the N-terminus and a non-
cleavable His6-tag to the C-terminus. This approach
enabled us to pool nondegraded protein in the successive
purification steps. In response to the presence of a truncated
fragment smaller than the catalytic domain construct in
preparations of ColT, two shorter variants were cloned to
identify an even smaller active catalytic domain. However,
both mini-constructs showed no catalytic activity in the
FALGPA assay, although they migrated on SEC at the
expected size, indicative of proper folding (data not
shown). Therefore, we consider the present S1 variants as
minimal versions of the catalytic domains. These observa-
tions, (1) C-terminally truncated isoforms in vivo (Bond
and Van Wart 1984a; Matsushita et al. 1999; Yoshihara et
al. 1994), (2) time dependent degradation of recombinant
full-length constructs, and (3) inactivity of C-terminally
truncated, “mini” catalytic domains, indicate that (auto-)
degradation plays, similar as observed for trypsin (Halangk
et al. 2002), an important role in the regulation of clostridial
collagenases.
In conclusion, we succeeded in establishing a generic
expression and purification strategy for clostridial collage-
nases in E. coli and implemented this strategy for three
important and representative examples. This system evades
the problems associated with homologous expression (i.e.,
co-purification of other clostridial toxins) and utilizes the
most widely used of all prokaryotic organisms for recom-
binant protein expression in pharmaceutical industry with
well-established GMP standards (Fukui et al. 1989;
Yamamoto et al. 2002). Based on the old but by far not
outdated workhorse E. coli, we can readily provide
milligram-amounts of high-grade (contamination-free,
monodisperse, mono-isoformic, and conformationally homo-
geneous) protein preparations needed in diverse biotechno-
logical fields and for various sophisticated downstream
applications. Moreover, based on this platform, a systematic
screening of chimeric constructs and of other mutants is
feasible which will help to identify key residues and motifs in
collagenolysis and enlighten the biochemical function of the
individual domains present in clostridial collagenases.
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